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ABSTRACT: Protein L (PpL) is a bacterial protein which is
used in the aﬃnity chromatography stage of the production of
monoclonal antibodies because of its ability to form high
aﬃnity complexes with the light chains of immunoglobulins. In
the present work, the binding interfaces between one domain
of PpL and antigen-binding fragments (Fab) have been
investigated adopting molecular dynamics with the aim of
determining the binding contribution of the residues located at
the Fab−PpL interface. Because it is known that PpL binds
antibodies through two distinct binding sites with diﬀerent
aﬃnities, simulations were performed for both sites to
determine interaction free energies to assess the relative
binding contribution of the two sites. Mutational studies were
then performed only on the dominant binding site. The
binding free energy was evaluated with the molecular mechanics Poisson−Boltzmann surface area (MMPBSA) and umbrella
sampling/weighted histogram analysis methods. Key residues for the formation of the dominant binding site complex were
identiﬁed by means of alanine scanning performed both for the Fab and PpL domains. Residues of the light chain of the antibody
that contribute most to binding were found to be located between SER7 and VAL13. Four residues from PpL are important for
the stability of the complex: PHE839, LYS840, GLU849, and TYR853. Three residues of PpL that do not contribute to the
interaction were mutated to histidine (HIS), which changes its protonation state as a function of pH, to ﬁnd whether this could
allow us to control the binding interaction energy. This can be useful in the elution stage of the aﬃnity chromatography
puriﬁcation of antibodies if PpL is used as a ligand. These residues are GLN835, THR836, and ALA837. Molecular dynamics
simulations with both protonated and unprotonated HIS were performed to mimic how changing pH may reﬂect on protein−
ligand interaction energies. The MMPBSA approach was used to evaluate the variation of the aﬃnity of the mutated systems with
reference to the wild type. Our results show that these mutations could help in disrupting the complex under acidic conditions
without impairing the aﬃnity of PpL for the light chains at higher pHs.
1. INTRODUCTION
Monoclonal antibodies (mAbs) are one of the most promising
classes of biological drugs, both for therapeutic and diagnostic
purposes, with a constantly growing signiﬁcance in the
pharmaceutical industry for the last 30 years. The mAb market
value in 2010 was of about $40 billion,1 and it is expected to be
of nearly $125 billion by 2020.2 Many formats of mAbs are
commercially available. Complete antibodies are formed by
fragment crystallizable (Fc) and antigen-binding fragments
(Fab) domains, whereas the antibody fragments are constituted
only by the regions that bind the antigens, such as Fabs and
single-chain variable fragments (scFvs). ScFvs consist of
variable domains of heavy and light chains, joined together
by a ﬂexible peptide linker. Both Fabs and scFvs penetrate
tumors much more rapidly than whole antibodies and have a
very short serum half-life because of their limited dimensions
(50 and 25 kDa, respectively).3 Because of the complexity of
these macromolecules and the presence of many diﬀerent
compounds in the production media, the puriﬁcation step of
the production of mAbs and antibody fragments is crucial. The
ﬁrst recovery step in the downstream processing of mAbs is
aﬃnity chromatography, a puriﬁcation methodology that is
based on the selective interaction between the solute in the
mobile phase to be puriﬁed and the aﬃnity ligand in the
stationary phase. The most common ligand for mAb
puriﬁcation is staphylococcal protein A,4 which shows a strong
aﬃnity for the Fc region of immunoglobulin G (IgG) and has
been largely studied in the last 30 years both experimentally
and in silico.5−15 Antibody fragments do not have the Fc
domain, thus protein L (PpL) is used in the puriﬁcation step,
instead of protein A or protein G.16 PpL is a cell wall protein of
the bacterium Peptostreptococcus magnus17 that contains four or
ﬁve homologous domains, depending on the bacterial strain,18
capable of binding the VL regions of κ1, κ3, and κ4 light chains
with strong aﬃnity (Kd ≈ 10−9 M), but not κ2 and λ
subgroups,19 with no restriction on the class of the Ig. The Ig
binding domains of PpL contain a four-stranded β-sheet with a
single α-helix, similarly to IgG binding domains of protein G
from group C and G Streptococci.20 PpL interacts with
antibodies through two independent binding sites, denoted
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here as binding site 1 and binding site 2. The ﬁrst interface
involves the second β-strand and the α-helix, whereas the other
involves the third β-strand and the α-helix.21 Both binding sites
interact with the second β-strand of the Vκ domain of Igs. VL
chains that do not bind PpL have been successfully engineered
to add the capability of binding PpL, by substituting the N-
terminal sequence corresponding to Vκ FR1 into the sequence
of the VL chain of the antibodies.
22,23 In this paper, we
investigate the interaction between one domain of PpL and Fab
fragments using molecular dynamics (MD) simulations with
the aim of determining free interaction energies between the
protein and the ligand for both binding sites and then evaluate
the contributions to the binding aﬃnity of the residues of both
PpL and Fab fragments for the dominant binding site. Then,
the eﬀect of mutations to histidine and of its protonation state
on the dominant binding site aﬃnity has been investigated. In
principle, this allows us to ﬁnd mutations of PpL that could
make the use of milder conditions possible during the elution
process of an aﬃnity chromatography puriﬁcation cycle because
the low pH used to recover the product, between 2 and about
3.5,24 can induce aggregation and conformational changes in
the antibodies.25,26 The rational is that the mutation of residues
that do not contribute to binding into histidines may help to
tune the interaction energy between the protein and the ligand.
In fact at pHs higher than about 5, histidine residues are usually
not protonated and are uncharged, and thus the mutation of a
nonbinding residue to histidine is not likely to impact
signiﬁcantly the strength of the protein−protein interaction.
As the pH decreases, histidines will eventually get protonated
and thus, most likely, lead to the establishment of repulsive
electrostatic interactions that will decrease the system
interaction energy.
2. RESULTS AND DISCUSSION
PpL interacts with the variable chain of antibodies through two
distinct binding sites. Interaction free energies for the PpL−Fab
complexes via both interfaces were evaluated using two
approaches. Crystal 1MHH was used to evaluate the free
energy of interaction of binding site 1 by means of the
molecular mechanics Poisson−Boltzmann surface area
(MMPBSA) approach, whereas crystal 1HEZ was used to
calculate the free energy of interaction of both binding
interfaces, using the MMPBSA and weighted histogram analysis
(WHAM) methodologies. In this section, the results of MD
simulations are discussed and compared with experimental
values available in the literature. In section 2.1, the results of
models of binding site 1 are reported, whereas the results of the
modeling of binding site 2 are presented in section 2.2. Finally,
in section 2.3, a mutational study has been conducted to
evaluate possible mutants of PpL that may allow milder elution
conditions during the elution phase of the puriﬁcation process.
2.1. Modeling of the Binding Site 1 Interaction. The
binding site 1 interaction between Fab fragments and a PpL
domain was investigated to evaluate the free energy of binding
and to identify the residues, from both PpL and the Fab
fragment, which contribute most to the strength of the aﬃnity
interaction. Two molecular models have been used to study the
ﬁrst binding interface. The starting structures were obtained
from the crystal structures deposited in the Protein Data Bank
as 1HEZ21 and 1MHH.27 The structure of the 1MHH complex
is shown in Figure 1.
MD simulations of 20−25 ns in explicit water were carried
out to study the conformational evolution of the Fab−PpL
complexes for the 1MHH and 1HEZ models, respectively.
Conﬁgurations from each simulation were saved every 10 ps for
further analysis.
The free energy of binding as a function of simulation time
was calculated using the MMPBSA approach. The results are
summarized and compared with the experimental value
reported by Beckingham et al.28 in Figure 2. The calculated
free binding energies averaged over the last 5 ns of each
simulation are reported in Table 1.
Polar and nonpolar contributions to the interaction free
energy are reported separately in Figure 3. The polar
contribution was evaluated as the sum of the polar terms of
ΔEMM and ΔGsol, which are the electrostatic energy calculated
with the Coulomb’s law using an inﬁnite cutoﬀ (ΔEcoul) and the
solvation free energy obtained solving the Poisson−Boltzmann
equation (ΔGPB). The nonpolar contribution was estimated as
the sum of van der Waals energy (ΔEvdW) and the free energy
associated with the solvent accessible surface area (ΔGSASA).
The data analysis shows that the interaction between PpL and
the antibody fragment is driven by nonpolar interactions,
whereas the polar contribution is unfavorable to the formation
of the complex. Formation of protein−ligand complexes is
often driven by nonpolar interactions because of the presence
of hydrophobic patches on the surface of the proteins involved
in the interaction. Although, in the case of the interaction
between Fab and PpL, the polar contribution is not favorable to
the formation of the binding, it is an important contribution to
the formation of other protein−ligand interactions involving
antibodies, like in the case of the IgG−protein A complex,7
which has been mentioned above. Fluctuations of the calculated
interaction energy shown in Figure 2 can be reasonably
attributed to the relaxation of the complexes from the initial
conformation obtained from the crystallographic structures.
This is the reason why the ﬁnal 5 ns of both simulations have
been used to evaluate binding free energies.
Curves for both models reported in Figure 2 show the
presence of peaks of few kcal/mol. The 1MHH model has a
peak at 7 ns, whereas the 1HEZ model shows a rapid variation
of the value of the binding free energy between 12 and 17 ns.
Comparing Figure 2 with Figure 3, it is possible to note that
these variations are due to ﬂuctuations of the polar contribution
to the overall binding free energy, given by the relaxation of the
proteins from the initial conﬁguration obtained from the
Figure 1. Structure of the PpL−Fab complex obtained from crystal
structure 1MHH used as the starting conﬁguration for the simulations.
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crystallographic structures. It is important to highlight that both
models converge to the same value of binding free energy,
averaged over the last 5 ns of each simulation, of about −10.50
kcal/mol. This value diﬀers from the average values calculated
over the entire simulation of −13.95 kcal/mol for the 1HEZ
model and −8.30 kcal/mol for the 1MHH model.
An alanine scanning analysis was performed on the residues
in the ﬁrst interface from both Fab and PpL to determine the
contribution of each residue to the aﬃnity binding. The results
of the analysis are shown in Figure 4.
The substitutions to alanine of ﬁve residues from the variable
chain of the Fab fragment cause an increase of ΔGbind between
2 and 4 kcal/mol. These residues are SER7, PRO8, LEU11,
VAL13, and GLU17. This is in agreement with what was shown
by Graille and co-workers,21 who compared the amino acidic
sequence of κ and λ subgroups of human VL chains,
highlighting that the PpL binding ability is concentrated
between THR5 and ALA12. In fact, three of them (SER7,
PRO8, and LEU11) are inside that interval, and one (VAL13)
is just one residue over. The relatively low contribution (less
than 4 kcal/mol) of these amino acids to the overall binding
energy is consistent with the fact that the interaction between
PpL and Fab fragments is dependent on the conformation of
the main chain.21
Four residues from PpL contribute signiﬁcantly to the
strength of the ﬁrst binding interface. These residues are
PHE839, LYS840, GLU849, and TYR853. PHE839 and
LYS840 are in the second β-strand, whereas GLU849 and
TYR853 are in the α-helix. The aromatic ring of PHE839 is
known to interact with the ring of PRO8 from the VL chain,
and this interaction has been used to perform ﬂuorometric
measurements substituting the phenylalanine with a trypto-
phan.29 GLU849 is involved in a salt bridge with LYS24 from
the VL chain, whereas LYS840 is involved in a hydrogen bond
with SER9. The greatest contribution to the aﬃnity between
PpL and the Fab is given by TYR853. This residue is well
known in the literature for its importance in the stability of the
interaction. Beckingham et al.28 have shown that the
substitution of TYR853 with a phenylalanine leads to a 23-
fold drop in aﬃnity. Roque et al.30 proposed an artiﬁcial ligand,
named ligand 8/7, that may resemble the pocket formed by
TYR853, PHE839, and GLU838. Svensson et al.31 estimated
the equilibrium dissociation constant with kinetic titration
experiments on some PpL mutations and found that the
greatest contributions to binding site 1 aﬃnity are from
PHE839 and TYR853, which is in good agreement with our
predictions. Our calculations also correctly show that TYR851,
which is an important residue for the strength of the aﬃnity
interaction of binding site 2,31 does not contribute to the
interaction of the ﬁrst interface. This is because TYR851,
though located in the α-helix of PpL like its homologous
TYR853, faces away from the binding site 1.
The key residues of PpL and the Fab fragment are shown in
Figure 5.
Figure 2. Binding free energy for the ﬁrst interface of PpL−Fab complexes (binding site 1) calculated with the MMPBSA approach as a function of
simulation time for the 1MHH and 1HEZ binding complexes and comparison with the experimental data.21
Table 1. Binding Free Energies of Binding Site 1 for Two
PpL−Fab Complexes Averaged Over the Entire Simulation
and Compared with the Value Averaged Over the Last 5 ns
of Simulation Calculated with the MMPBSA Approach




Figure 3. Polar and nonpolar contributions to the binding free
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2.2. Modeling of Binding Site 2. The second binding
interface was investigated through 25 ns of MD simulation in
explicit water starting from the 1HEZ crystal structure. The
MMPBSA has been used to estimate the free energy of
interaction. In Figure 6, the result of the MMPBSA calculation
is reported. In this case, the model is unable to reproduce the
experimental value of 7 kcal/mol reported by Graille et al.,21
and a drift toward lower values of the calculated binding free
energy is present. This seems to suggest that the system is
reaching a state that is more stable than the initial
Figure 4. Variation of the binding free energy for the ﬁrst binding interface calculated substituting the amino acids of (a) Fab and (b) PpL with
alanine.
Figure 5. Key residues of binding site 1 identiﬁed with alanine scanning analysis for (a) Fab and (b) PpL.
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conﬁguration, but important conﬁgurational modiﬁcations in
the structure of both Fab and PpL have not been observed
during the simulation time. A possible reason is that
conformational changes during the formation of the complex
determine an error in the energy estimation through the
MMPBSA protocol. One of the hypotheses underlying the one-
trajectory approach for the MMPBSA is that no conformational
change occurs during the formation of the complex. This is
because to compute the binding free energy with this approach,
only one MD simulation of the complex is required, and the
sampling of the conformations of the protein and the ligand is
obtained from the sampling of the complex. Alternatively, it
might be that the modiﬁcation of the protein structure done by
Graille et al. to investigate separately the contributions of the
two binding sites to the complex modiﬁes the protein binding
properties. This complicates our interpretation of the
experimental results as it makes the identiﬁcation of the
dominant binding site unclear, which is necessary to focus our
in silico mutational study properly. To further investigate this
aspect, we decided to determine the protein binding energy at a
higher level of theory.
A ﬁrst possibility to improve the quality of the MMPBSA free
energy predictions would be to run additional MD simulations
of the protein and the ligand, so that conformations of the
unbound state may be properly sampled. Unfortunately, this
three-trajectory approach, though slightly more computation-
ally demanding, suﬀers from the problem that intermolecular
terms in the calculation of the molecular mechanics energy do
not cancel out, thus adding a signiﬁcant numerical noise to the
computational results. For this reason, we chose to use the
computationally much more demanding, but more accurate,
WHAM approach. The distance between the centers of mass
(COMs) of PpL and Fab was used as reaction coordinate. This
is motivated by the fact that both Fab and PpL do not undergo
large conformational variations, keeping their native fold. 58
windows were used for the umbrella sampling (US)
simulations, with a constant spacing of 0.5 Å, from 25.5 to
54.0 Å. A harmonic constant of 19 kcal mol−1 Å−2 was used to
force the system in the center of the windows. The calculated
potential of mean force (PMF) is shown in Figure 7. The
calculated interaction free energy for the second interface is
7.25 kcal/mol, thus in excellent agreement with the value
reported by Graille et al.21 mentioned above and supporting
our interpretation of the probable cause of the discrepancy
between MMPBSA and experimental data. The absolute
minimum of the PMF is at a distance between the COMs of
28 Å. After that, a ﬁrst steep rise of 3 kcal/mol of the potential
is found at 35 Å, where the system reaches an intermediate
state, whereas a second rise takes place at 45 Å, where a plateau
is reached and the two molecules get unbound. Analyzing the
MD trajectories it could be observed that the ﬁrst steep rise of
the PMF at 35 Å is due to the disruption of the hydrogen bond
formed by TYR851 and the backbone of the VL chain of the
Fab. The plateau between 35 and 45 Å is correlated to the
rotation of PpL around the bonding interaction of PHE843 and
ASN873 with ARG18. This interaction is then broken at 45 Å,
which determines the second steep rise of the PMF.
The present computational results support the experimental
results, indicating the aﬃnity by PpL and that the antibody is
dominated by binding site 1. In the following, therefore, we
focused our study on the possibility to tune the energy of this
interaction on the modiﬁcation of residues that were found to
be located in the proximity of binding site 1.
2.3. Mutational Study. A typical aﬃnity chromatography
cycle is formed by an application phase, where the protein−
ligand complex is established, and an elution phase, where the
interaction is disrupted by means of a variation in ionic strength
or buﬀer pH. To allow the release of the antibody from the
ligand, a pH lower than 4 is often required, but a low pH can
damage the product leading to denaturation and/or aggrega-
tion,32 and thus milder conditions are preferable. One way to
make the use of milder conditions possible is making the
interaction between the protein and the ligand weaker during
the elution phase, possibly without making the interaction
weaker during the application phase. To do so, we tested three
mutations to histidine of PpL residues located in the protein−
ligand interface of binding site 1, the dominant binding site
among the two studied here, that have a low contribution to the
stability of the complex. The residues from PpL that we chose
to mutate are GLN835, THR836, and ALA837 from the
1MHH model. All the mutated residues are located in the
second β-strand of the PpL domain. For each mutation, we
performed two MD simulations, testing both the protonated
and the deprotonated state of the imidazole ring, with the aim
of mimicking a change in pH. Free energies of interaction have
been calculated with the MMPBSA approach and have been
compared with the reference value. The results are reported in
Figure 8.
Figure 6. Binding free energy of binding site 2 for the PpL−Fab
complex calculated using the MMPBSA approach and reported as a
function of simulation time.
Figure 7. PMF for the second binding interface evaluated as a function
of the distance between the COMs of PpL and Fab.
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It can be noted that, for the residues mutated to
deprotonated histidine (HISE), no weakening of the interaction
should occur during the application phase of the chromato-
graphic cycle, but in the case of GLN835, the aﬃnity can
increase by about 4 kcal/mol. For all the mutations to
protonated histidine (HISP), a weakening of the interaction
could occur during the elution phase, allowing milder
conditions during the process. The weakening of the
interaction may be due to the proximity of these residues
with positively charged residue of the VL chain or with polar
residues of the PpL domain that interact with the VL chain. In
particular, ALA837 is close to TYR853, which is one of the
most important residues to the aﬃnity interaction. TYR853
interacts with THR20 in the VL chain by means of a hydrogen
bond between the hydroxyl group of tyrosine and the backbone
of the VL chain. This hydrogen bond may be weakened by the
presence of the positive charge of the protonated HIS837.
Svensson et al.31 report that the mutation of the same residue
to arginine disrupts binding site 1.
3. CONCLUSIONS
The interaction between Fab fragments and PpL has been
investigated using MD simulations. PpL binds antibodies via
two distinct binding sites. Molecular models of both
interactions have been built from crystal structures available
in the Protein Data Bank. These molecular models have been
used to estimate the binding free energy of both the
interactions, by means of two diﬀerent approaches, MMPBSA
and WHAM. Values of the free energy of interaction have been
compared with those available in the literature. The properties
of the ﬁrst binding interface have been investigated through an
alanine scanning analysis that allowed us to identify the residues
that contribute most to the aﬃnity binding. This analysis
conﬁrms that the aﬃnity of PpL for the antibodies is dependent
on the conformation of the light chain. The key residues of κ
light chains are mostly located in the second β strand. Four
residues of PpL establish strong interactions with the light
chains. These residues, namely PHE839, LYS840, GLU849, and
TYR853, have been often mutated to study and disrupt the ﬁrst
binding interface. The results of the alanine scanning analysis
agree with the data reported in the literature. From the alanine
scanning analysis, we identiﬁed three possible single-point
mutations to histidine that could be exploited to allow milder
conditions for the desorption of the antibodies during the
elution stage. The mutated residues are GLN835, THR836, and
ALA837 and belong to the second beta strand of PpL. These
mutations can be tested experimentally to validate the
molecular model presented here.
4. METHODS
4.1. Molecular Models. Molecular models of the
interaction between PpL and Fab fragments were built starting
from two crystal structures available in the Protein Data Bank
(PDB ID: 1HEZ21 and 1MHH27). The 1HEZ crystal is
composed by one C* domain of PpL33 in complex with two
Fab fragments of human IgM. This structure was used to model
the interaction between PpL and Fab fragments via both
binding interfaces: binding site 1 interaction was modeled using
chains A, B, and E, whereas binding site 2 was modeled using
chains C, D, and E. The 1MHH crystal structure includes two
complexes formed by PpLD55A domains with murine Fab with a
VLκ9 region. We used one of the two complexes (chains A, B,
and E) to model the binding site 1 interaction.
The heavy chains of the Fab fragments in both crystal
structures have missing residues. They were rebuilt by
homology modeling using the MODELLER interface in
UCSF Chimera 1.6.1.34 Chain F from crystal structure
1DEE8 and chain D from crystal structure 1YMH35 were
used as templates to build the homology model of the heavy
chains of structures 1HEZ and 1MHH, respectively.
4.2. Free Energy Calculations. Interaction free energies
between PpL and Fab were evaluated by means of two
computational methodologies. The ﬁrst approach is
MMPBSA,36 and the other one is the WHAM, which was
used to reconstruct the PMF from US simulations.37
4.2.1. MD Simulations. All MD simulations were performed
in explicit water and ions with an ionic strength of 150 mM.
Periodic boundary conditions were applied, and long range
electrostatic interactions were evaluated with the particle mesh
Ewald method38 with a nonbonded cutoﬀ of 10 Å. All MD
simulations were performed at 300 K and 1 bar. The
temperature was controlled using the v-rescale algorithm.39
Protein and nonprotein molecules have been controlled
separately to avoid the hot solvent/cold solute eﬀect.40 The
pressure has been controlled using the Parrinello−Rahman
algorithm.41 All bond lengths have been constrained using
LINCS,42 which allowed a time step of 2.0 fs. MD simulations
have been performed using the GROMACS 4.5.5 package.43
Proteins and ligands were modeled with the AMBER03 force
ﬁeld,44 and the TIP3P force ﬁeld45 was used to model water
molecules. MD simulations have been prepared following a
two-step protocol: 1000 steps of energy minimization with the
steepest descent algorithm to remove unfavorable contacts
between the solvent and the solute, followed by 100 ps of
position-restrained dynamics to let water molecules distribute
themselves around the solute at a constant volume and a
constant temperature, using a position restraint on the heavy
atoms of the solute with a harmonic constant of 2.4 kcal mol−1
Å−2.
4.2.2. Molecular Mechanics Poisson−Boltzmann Surface
Area. The MMPBSA approach allows us to evaluate the free
energy of binding ΔGbind for a protein−ligand complex as the
sum of three terms:
Δ = Δ − Δ + ΔG E T S Gbind MM gas solv (1)
Figure 8. Variation of binding free energy for single-point mutations
to protonated (HISP) and not protonated (HISE) histidines using the
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where ΔEMM is the molecular mechanics contribution in the gas
phase, calculated as the sum of electrostatic and van der Waals
energies. The entropic term, TΔSgas, was evaluated as the
diﬀerence of rotational and translational entropy in the gas
phase between the complex, Fab, and PpL. This term was
computed through statistical thermodynamics referring to the
corresponding molecular partition functions. The vibrational
contribution to TΔSgas has been neglected, mainly because of
the diﬃculty of estimation for large protein molecules. Not
taking into account, this term is likely to introduce an
uncertainty of few kcal/mol in the calculated binding free
energy. For the Fab−PpL complexes, the TΔSgas contribution is
about 34 kcal/mol. Finally, ΔGsol is the free energy of solvation,
evaluated as the sum of polar and nonpolar terms. The polar
term is calculated by solving the Poisson−Boltzmann equation,
whereas the nonpolar term is evaluated as a function of the
change in SASA of the proteins
γΔ = Δ +‐G bSASAnon polar (2)
where γ = 5 cal mol−1 Å−2 and b = 860 cal mol−1.46 All the
right-side terms in eq 1 are evaluated as the diﬀerence of the
value for the complex and the value for Fab and PpL.
The g_energy program in GROMACS 4.5.5 was used to
determine the molecular mechanics energy contribution. The
g_sasa program was used to evaluate the SASA for complex,
protein, and ligand conﬁgurations. The APBS 1.3 program47
was used to determine the polar contribution to free energies of
solvation. The pdb2pqr program48 was used to create the input
ﬁles for APBS. Conﬁgurations of the Fab−PpL complexes for
the MMPBSA calculations were generated with 20−25 ns of
MD simulations in a 10 × 10 × 10 Å simulation box. Structures
of Fab−PpL complexes have been collected every 10 ps.
Structures of Fab and PpL have been obtained from the
structures of the complexes, following the single-trajectory
approach.49
4.2.3. Potential of Mean Force. The PMF relative to the
unbinding process of the second interface has been recovered
from US simulations using the WHAM. The starting
conﬁguration of the complex was extracted from the last
frame of the MD simulation of the 1HEZ model. The complex
was then rotated to align the COMs of PpL and Fab along the
y-axis of the solvation box. Simulations were performed in a box
of 10 × 13 × 10 Å. PpL was progressively removed from the
Fab fragment through a series of MD simulations where the
distance between the COM of PpL and Fab have been
constantly increased with steps of 0.5 Å by applying a 24 kcal
mol−1 Å−2 harmonic potential along the y-axis. The last
snapshot of each simulation was used as the starting point for
US simulations where the distance of COMs of PpL and Fab
was restrained by applying a 19 kcal mol−1 Å−2 harmonic
potential. The values of the distance between the COMs of PpL
and Fab have been saved every 100 fs for WHAM analysis.
WHAM equations were solved using our in-house code50 until
the diﬀerence between two successive values of the PMF diﬀers
by less than 10−5 kcal/mol.
4.2.4. Computational Alanine Scanning. An alanine
scanning analysis of the ﬁrst interface was performed to
determine the amino acidic contribution to the free energy of
binding using the 1MHH molecular model. Nonalanine and
nonglycine residues in the Fab−PpL interface were mutated
one by one to alanine, and the free energies of binding for the
mutated systems were then evaluated following the MMPBSA
approach36 described in section 4.2.2. Because the side chain of
alanine is constituted only by a methyl group, mutations of the
residues to alanine were done by deleting all the atoms of the
side chain but the Cβ. Hydrogens of the mutated side chain
were then added with the pdb2gmx program. Binding free
energy for the mutated system was compared with the value
obtained for the wild type protein to identify the residues that
contribute to aﬃnity binding. The structures of the complex
used for the analysis have been extracted from the last 5 ns of
the trajectory of the 1MHH model.
4.2.5. Mutational Study. The strong aﬃnity between
antibodies and Ig binding proteins, such as PpL, protein G,
and protein A, has the drawback of requiring harsh conditions
during the elution phase, like pH well under 4.0, to disrupt the
binding and recover the puriﬁed antibody. The very low pH can
induce agglomeration and loss of the native conformation of
the product. A possible way to circumvent this problem is to
engineer the aﬃnity ligand to allow the desorption under
milder conditions. This is done by mutating one or more
residues in the binding interface. A notable approach is the
mutation of residues to histidine to obtain a pH-dependent
binding. In fact, histidine residues have an imidazole side chain
that switches between protonated and unprotonated states at
slightly acidic pH, near its pKa. Point mutations to histidine
have been performed on protein G and PpL allowing higher pH
during the elution phase.51,52 To ﬁnd possible mutations to
histidine that could allow an easier desorption of antibodies
from PpL during the elution phase, we identiﬁed three residues
belonging to the ﬁrst binding interface of PpLD55A that do not
contribute to the binding aﬃnity. These residues were mutated
to histidine using the rotamers tool available in the UCSF
Chimera 1.6 software.53 The protonation state of the mutated
histidine was then selected with the pdb2gmx program in
GROMACS 4.5.5. For each structure, two models have been
created: one with a neutral histidine (HISE), to simulate the
adsorption stage of the aﬃnity chromatography cycle, and the
other with a charged histidine (HISP), to mimic the low pH
conditions of the elution stage. MD simulations (20 ns) have
been carried out, and the relative binding free energies with
respect to the 1MHH model were evaluated by means of the
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